Novartis announced that the Phase III COMBI-I trial of the company’s experimental checkpoint inhibitor spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to hit the primary endpoint in melanoma.
https://www.pharmalive.com/wp-content/uploads/2020/08/Novartis’-Spartalizumab-Combo-Flunks-Phase-III-Melanoma-Study-BioSpace-8-24-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-08-24 16:25:202020-08-25 13:06:31Novartis’ Spartalizumab Combo Flunks Phase III Melanoma Study